

Goal: End the Epidemic

**Develop coordinated clinical
research plan**

Goal: End the Epidemic

Develop coordinated clinical research plan

- **Stop new infections**
 - **Protect uninfected persons**
 - **Reduce infectiousness of infected persons**
- **Keep infected persons healthy**
- **Continue to pursue innovative translational research**

Issues To Be Considered

Continuum of Approaches

- **Applicability**
 - **“Optimal” therapies ↔ cost effective and deliverable interventions**
 - **Timelines**
 - **Learn as much as possible from each trial (slower, resource intensive ↔ less slow and focused)**
- **Individual RCT ↔ community RCT**
- **Individual recruitment ↔ family focus**
- **Domestic ↔ international ‘agenda’**
- **“Long term clinical outcome ↔ “surrogate markers”**

Issues To Be Considered

Continuum of Approaches

- **Routes of exposure**
 - **Vaginal, rectal, perinatal (peripartum, breastfeeding), parenteral, oral**
- **Ages**
 - **Adults, adolescents, newborns, perinatal**
- **Focus?**

Stop New Infections

- **Protect uninfected**
 - **Vaccines**
 - **Microbicides**
 - **Therapies/vaccines**
 - **Coinfections, particularly genital ulcerative infections**
 - **Behavior**
 - **Barrier methods**
- **Reduce infectiousness of infected**
 - **Reduce viral load and/or shedding**
 - **ART, co-infection treatment, vaccines?**
 - **Modify transmission events**
 - **Behavior, barrier methods**

Stop New Infections

- **HIV Vaccines - issues**
 - **Multi-country trials**
 - **Clade issue**
 - **Background issue (HLA/genetic, other)**
 - **How many countries/populations?**

Stop New Infections

- **Vaccines**
 - **2-3 efficacy trials; impact on infection, disease progression and secondary transmission**
 - **RCT and also community based?**
 - **Selection and improvement**
 - **Selection of most promising candidates**
 - **Approaches to compare candidates, e.g. pox vectors**
 - **Continued improvement in vaccine design**
 - **Antibody !!!**

Stop New Infections

- **Passive transfer in MTCT**
 - **Selection of best possible combinations for “proof of concept” in MTCT setting**

Stop New Infections

- **Microbicides - issues**
 - **Adherence and selection of control arm(s)**
- **Science**
 - **1-2 phase III trials**
 - **RCT**
 - **Placebo vs. condom-only arm as comparison**
 - **Selection of most promising products**
 - **New microbicide design**

Stop New Infections

- **Behavior (individual, community)**
 - **Impact VCT on transmission in RLDC**
- **Barriers (male vs. female)**
- **Treatments (ART, Co-infections)**
- **Vaccines (HPV?)**

Keep Infected Persons Healthy

- **When to start and with what; when to switch**
 - Early initiation or deferred therapy
 - Adherence, cost-benefit, drug conservation
- **Resistance and salvage**
 - Sequencing regimens to retard resistance
 - New approaches for highly treated - new RX
- **Immune preservation or restoration**
 - Immune modulation to augment lymphocyte number or function
 - “Therapeutic” vaccines

Keep Infected Persons Healthy

- **Co-infections/Concomitant Meds**
 - Tuberculosis
 - Hepatitis – B, C and GBVc
 - Malaria
 - Natural products
- **Reduce or control complications**
 - Managing CV, GI and neuro signs and sx
 - Developing new drug regimens
- **Simplify diagnosis, monitoring, delivery**

Examples of Coordinated Science

- **Common trials – single trial jointly planned and conducted**
 - **AVEG/HPTN phase II trial**
- **Simultaneous trials**
 - **HPTN052, AACTG 5175, AACTG 5190**
- **Trials conducted in the same setting**
- **Data sharing**

Examples of Coordinated Science

- **Impact of prevention and ART on transmission**
- **Rx of HIV+ women in RLDC and impact on MTCT**
 - **Research relevant to family members**
- **Rx and prevention vaccine research**
 - **Common correlates?**

Examples of Coordinated Science

- **Studies of acute infection; viral dynamics; reservoirs**
 - Vaccines, Rx, microbicides
- **Cross-cutting lab research**
 - Diagnosis, endpoint monitoring (viral load, CD4), immune assays, other?
- **Cross-cutting background issues**
 - Nutrition, traditional therapies, endemic infections

Examples of Coordinated Science

- **Impact of prevention and ART on transmission**
- **Rx of HIV+ women in RLDC; impact on MTCT**
- **Rx and prevention vaccine research**
- **Studies of acute infection**
- **Cross-cutting lab research**
- **Cross-cutting background issues**

➤ YOUR IDEAS ? PRIORITIES?